Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_2
2
22%
Ph phase_3
7
78%

Phase Distribution

0

Early Stage

2

Mid Stage

7

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
7(77.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(7)
Terminated(2)

Detailed Status

Completed7
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
77.8%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (22.2%)
Phase 37 (77.8%)

Trials by Status

terminated222%
completed778%

Recent Activity

0 active trials
Showing 5 of 9
terminatedphase_2

Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line

NCT01567904
completedphase_3

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

NCT00679588
completedphase_3

Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery

NCT00709904
completedphase_3

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery

NCT00721760
completedphase_3

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery

NCT00718224
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT01567904Phase 2

Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line

Terminated
NCT00679588Phase 3

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

Completed
NCT00709904Phase 3

Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery

Completed
NCT00721760Phase 3

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery

Completed
NCT00718224Phase 3

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery

Completed
NCT00694382Phase 3

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

Completed
NCT00697099Phase 3

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery

Completed
NCT00714597Phase 3

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility

Terminated
NCT00331838Phase 2

Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9